Glaukos Corp Files 8-K for Regulation FD Disclosure

Ticker: GKOS · Form: 8-K · Filed: Dec 9, 2024 · CIK: 1192448

Sentiment: neutral

Topics: disclosure, regulation-fd

Related Tickers: GKOS

TL;DR

Glaukos just filed an 8-K for a Reg FD disclosure. Watch for news.

AI Summary

On December 9, 2024, Glaukos Corporation filed an 8-K report. The filing primarily concerns a Regulation FD Disclosure, indicating that the company is providing material non-public information to the public. Specific details regarding the nature of this disclosure, such as financial figures or strategic announcements, are not provided in the excerpt.

Why It Matters

This filing signifies Glaukos Corporation is making a public disclosure of information, which could impact investor understanding of the company's current status or future prospects.

Risk Assessment

Risk Level: low — The filing is a standard disclosure and does not inherently present new risks, but the content of the disclosure itself could be material.

Key Players & Entities

FAQ

What specific information is being disclosed under Regulation FD?

The provided excerpt does not specify the content of the Regulation FD disclosure, only that one was made on December 9, 2024.

What is the significance of a Regulation FD Disclosure filing?

A Regulation FD Disclosure filing means the company is disseminating material non-public information to the public, ensuring fair disclosure to all investors.

When was this 8-K filing submitted?

The filing was submitted on December 9, 2024.

What is Glaukos Corporation's primary business?

Glaukos Corporation is in the business of Surgical & Medical Instruments & Apparatus, as indicated by its SIC code 3841.

Where is Glaukos Corporation headquartered?

Glaukos Corporation is headquartered at One Glaukos Way, Aliso Viejo, California, 92656.

Filing Stats: 524 words · 2 min read · ~2 pages · Grade level 12.4 · Accepted 2024-12-09 06:30:13

Key Financial Figures

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. In a Current Report on Form 8-K filed with the Securities and Exchange Commission on December 3, 2024, Glaukos Corporation (the "Company") previously disclosed that on December 2, 2024, it had entered into unwind agreements (the "Capped Call Unwind Agreements") with certain financial institutions (the "Option Counterparties") relating to a portion of the capped call transactions that were previously entered into by the Company with such Option Counterparties in connection with the issuance of its 2.75% Convertible Senior Notes due 2027 (the "Notes") in an aggregate principal amount of $287.5 million. The Capped Call Unwind Agreements relate to a portion of capped call transactions corresponding to fifty percent of the number of shares of the Company's common stock initially underlying the Notes. Pursuant to the Capped Call Unwind Agreements, the Option Counterparties delivered to the Company approximately $53.2 million, which amount was determined based upon the volume-weighted average price per share of the Company's common stock during the averaging period from December 3, 2024 through December 5, 2024. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GLAUKOS CORPORATION (Registrant) By: /s/ Alex R. Thurman Name: Alex R. Thurman Title: Senior Vice President & Chief Financial Officer Date: December 9, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing